Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers study effects of cannabis on sedation, cancer treatment symptoms

2.

Combo Therapy Boosts Early CML Response but Not Long Term

3.

Relationship-building key to addressing oncologist shortages in rural care

4.

More men with prostate cancer are avoiding unnecessary surgery

5.

Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot